Independent Medical Education Grants

Programs that provide education on the use of 4F-PCC in: warfarin reversal, GI bleeding, ICH, trauma, treatment of direct oral anticoagulant (DOAC)-associated bleeding, bleeding in cardiac surgery and health economic aspects of blood management and concentrate administration.

Programs that increase the awareness and understanding of the role of fibrinogen in acute hemorrhage control.

Programs that educate on the use of fibrinogen concentrate in clinical scenarios, including, but not limited to cardiac surgery, postpartum hemorrhage, trauma, and liver transplant.

Programs designed to enhance understanding and medical expertise in classical hematology, with a particular focus on supporting early-stage researchers and clinicians.

Programs that educate on the real-world use of extended half-life FIX therapies and the importance of FIX activity levels and their correlation with clinical outcomes in hemophilia B.

Programs that describe the real-world use of plasma derived therapies for long-term prophylaxis in the treatment of von Willebrand disease.

Programs designed to educate on provider and patient real-world experience with hemophilia B gene therapy.

Programs that educate on the key outcome and clinical differences between hemophilia gene therapy treatment options for hemophilia A and B, focusing on durability, transaminitis, and corticosteroid use.

Programs that educate on gene therapy for hemophilia B and the importance of FIX activity levels and their correlation with clinical outcomes.

Programs that enhance clinician’s knowledge of hereditary angioedema types I, II and HAE with normal C1 inhibitor including but not limited to: epidemiology, differential diagnosis, clinical signs and symptoms, pathophysiology, guideline driven management and/or current/novel treatments.

Role of shared decision making between HCP and patient in determining their appropriate HAE management plan.

Programs that raise awareness around the HAE patient journey, real-world evidence, and quality of life aspects of their disease.

Programs pertaining to the management of HAE patients relevant to the managed care community.

Programs pertaining to the MOA of factor XIIa or C1 Inhibitor in the contact activation system, or in clinical scientific research

Programs that discuss efficacy and safety of immunoglobulin therapy in special populations with neuromuscular disorders, especially Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

Programs that enhance awareness of appropriate diagnostic assessment criteria and improve timely diagnostic accuracy.

Programs that foster knowledge of appropriate management and assessment of patient outcomes.

Programs that expand the knowledge of patient management using intravenous and subcutaneous immunoglobulin therapy through education on the clinical data, including infusion training of healthcare professionals.

Programs that bridge clinical practice gaps in neuromuscular disease management.

Programs that support the use of immunoglobulin therapy for management of CIDP.

Programs that raise awareness of disease burden and improve accurate diagnosis, particularly in adult populations with a history of non-infectious complications (e.g., chronic lung disease, autoimmune diseases).

Programs that expand the knowledge of therapeutic strategies for management of antibody deficiencies, including secondary immunodeficiencies.

Programs that enhance awareness of appropriate diagnostic assessment criteria and improve timely diagnostic accuracy.

Programs that foster knowledge and improve quality and delivery of care, utilization of appropriate therapy, and assessment of patient outcomes.

Programs that discuss innovations in the delivery of immunoglobulins.

Programs that support the use of immunoglobulin therapy for management of PID or SID.

A: You will receive a Grant submission confirmation via email which will include your Request ID. Please keep this for your records. This email will also provide a link to the Grant application to continue to follow up on the request.

A: You will receive an email notification of the status of the Grant after the Committee completes the review.